文献速递中毒与环境急症消化、代谢与肾脏急症

阿片类物质使用障碍初级保健临床决策支持系统:一项随机临床试验

Clinical Decision Support System for Primary Care of Opioid Use Disorder: A Randomized Clinical Trial.
PubMed 文献 · JAMA Intern Med · 2025-01-01
一句话结论在初级保健中,电子病历整合的临床决策支持系统增加了纳洛酮处方和阿片类物质使用障碍治疗订单,但未改变90天内MOUD覆盖天数或过量/死亡发生率。

这项实用整群随机临床试验于2021年4月至2023年12月在美国4个州3个卫生系统的初级保健诊所开展,评估电子病历整合的临床决策支持系统(CDSS)对阿片类物质使用障碍(OUD)诊断和治疗的影响。共纳入10891例符合标准的患者,干预组在30天内纳洛酮订单(1.4% vs 0.7%;OR 1.76;95%CI 1.14-2.72)和MOUD或转诊订单(14.0% vs 9.4%;OR 1.48;95%CI 1.05-2.08)均高于常规护理组,但OUD诊断率无差异。90天内MOUD覆盖天数中位数两组相似(84天 vs 83天;率比1.00;95%CI 0.93-1.08),干预期间过量或死亡发生率也无差异。作者认为OUD CDSS有助于增加初级保健中OUD治疗的可及性。

要点

  • 在初级保健中,CDSS使30天内纳洛酮订单从0.7%升至1.4%(OR 1.76;95%CI 1.14-2.72)。
  • CDSS使30天内MOUD或专科转诊订单从9.4%升至14.0%(OR 1.48;95%CI 1.05-2.08)。
  • CDSS未增加30天内OUD诊断率(两组无差异)。
  • 90天内MOUD覆盖天数中位数干预组84天 vs 常规护理组83天(率比1.00;95%CI 0.93-1.08),无差异。
  • 干预期间过量或死亡发生率两组无差异。

适用人群与场景

  • 年龄18至75岁、就诊于随机化诊所、且过去2年内有OUD诊断、过去6个月内有过量史或风险评分提示OUD或过量高风险的患者。
  • 研究场所为美国4个州3个卫生系统的初级保健诊所。

诊断标准与关键阈值

  • 高风险患者定义为无基线OUD诊断但风险评分提示OUD或阿片类过量高风险。
  • 主要结局指标为首次合格(索引)就诊后30天内接受OUD诊断(限于无基线OUD诊断的高风险患者)、纳洛酮处方、MOUD处方或专科转诊,以及索引后90天内MOUD处方覆盖天数。

研究设计与关键结果

  • 研究类型为实用整群随机临床试验,纳入10891例患者,5918例(54.3%)为女性,平均(SD)年龄48.0(13.9)岁。
  • 30天内OUD诊断率两组无差异。
  • 30天内纳洛酮订单:干预组80/5538(1.4%) vs 常规护理组40/5353(0.7%);OR 1.76;95%CI 1.14-2.72。
  • 30天内MOUD或治疗转诊订单:干预组775/5538(14.0%) vs 常规护理组503/5353(9.4%);OR 1.48;95%CI 1.05-2.08。
  • 90天内MOUD覆盖天数中位数(IQR):干预组84(55-90)天 vs 常规护理组83(55-90)天;率比1.00;95%CI 0.93-1.08。
  • 干预期间过量或死亡发生率两组无差异。

证据类型、等级与局限

  • 证据类型:整群随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为OUD CDSS可以帮助增加初级保健中OUD治疗的可及性。
  • 原文未据此给出其他推荐。

指南或共识出处

  • 临床试验注册号:NCT04198428。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Nearly 727 000 individuals in the US died of opioid overdoses between 1999 and 2022. The current workforce of addiction medicine specialists is inadequate to address the scale of this crisis, and primary care clinicians (PCCs) do not feel sufficiently supported to treat opioid use disorder (OUD).

OBJECTIVE: To evaluate whether an electronic health record-integrated clinical decision support system (CDSS) increases OUD diagnosis and treatment in primary care.

DESIGN, SETTING, AND PARTICIPANTS: This pragmatic cluster randomized clinical trial was conducted from April 2021 to December 2023. Primary care clinics in 3 health systems in 4 US states were randomized to receive or not receive an electronic health record-integrated CDSS aimed at improving OUD diagnosis and treatment. Eligible patients were aged 18 to 75 years, visited a randomized clinic, and had an OUD diagnosis in the last 2 years, opioid overdose in the last 6 months, or risk score indicating high risk of OUD or opioid overdose. Data were analyzed from September 2023 to October 2024.

INTERVENTIONS: The OUD CDSS provided personalized treatment recommendations to patients and PCCs in intervention clinics.

MAIN OUTCOMES AND MEASURES: Primary outcomes were likelihood to receive (1) an OUD diagnosis (among high-risk patients without a baseline OUD diagnosis), (2) a naloxone prescription, or (3) a prescription of a medication for OUD (MOUD) or specialty referral, all within 30 days of first eligible (index) visit, and (4) days covered by a MOUD prescription in the 90 days after index.

RESULTS: Among 10 891 patients meeting eligibility criteria, 5918 (54.3%) were female, and the mean (SD) age was 48.0 (13.9) years. There was no difference in OUD diagnoses within 30 days between groups. Patients in the intervention group had more naloxone orders (80 of 5538 [1.4%] vs 40 of 5353 [0.7%]; odds ratio, 1.76; 95% CI, 1.14-2.72) and orders for MOUDs or treatment referral (775 of 5538 [14.0%] vs 503 of 5353 [9.4%]; odds ratio, 1.48; 95% CI, 1.05-2.08) within 30 days. There were no differences in median (IQR) days covered by MOUD over 90 days postindex between intervention (84 [55-90] days) and usual care (83 [55-90] days; rate ratio, 1.00; 95% CI, 0.93-1.08) or in overdose or death rates during the intervention period.

CONCLUSIONS AND RELEVANCE: In this cluster randomized clinical trial, the intervention improved rates of naloxone orders and OUD treatment in primary care but did not affect days covered by a MOUD over 90 days postindex or overdose or death rates. These findings demonstrate an OUD CDSS can help increase access to OUD treatment in primary care.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04198428.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Rossom RC, Crain AL, Wright EA, et al. Clinical Decision Support System for Primary Care of Opioid Use Disorder: A Randomized Clinical Trial. JAMA Intern Med. 2025. PMID: 40658392. doi:10.1001/jamainternmed.2025.2535

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。